Organon & Co (OGN)
Total asset turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
---|---|---|---|---|
Revenue | US$ in thousands | 6,263,000 | 6,174,000 | 6,304,000 |
Total assets | US$ in thousands | 12,058,000 | 10,955,000 | 10,681,000 |
Total asset turnover | 0.52 | 0.56 | 0.59 |
December 31, 2023 calculation
Total asset turnover = Revenue ÷ Total assets
= $6,263,000K ÷ $12,058,000K
= 0.52
The total asset turnover ratio for Organon & Co. has been on a declining trend over the past five years, decreasing from 0.74 in 2019 to 0.52 in 2023. This indicates that the company's ability to generate sales from its total assets has been weakening over time. A lower total asset turnover ratio may suggest that the company is not efficiently utilizing its assets to generate revenue. Further investigation into the company's operations and asset management efficiency may be necessary to address the declining trend in total asset turnover.
Peer comparison
Dec 31, 2023
Company name
Symbol
Total asset turnover
Organon & Co
OGN
0.52
Abbott Laboratories
ABT
0.54
AbbVie Inc
ABBV
0.40
Alkermes Plc
ALKS
0.77
Amphastar P
AMPH
0.43
ANI Pharmaceuticals Inc
ANIP
0.50
Arcus Biosciences Inc
RCUS
0.11
Biomarin Pharmaceutical Inc
BMRN
0.35
Bristol-Myers Squibb Company
BMY
0.47
Catalent Inc
CTLT
0.45
Catalyst Pharmaceuticals Inc
CPRX
0.85